An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).

Authors

Mariko DeWire
Maryam Fouladi
David C Turner
Cynthia Wetmore
Cynthia Hawkins
Eugene I. Hwang, George Washington UniversityFollow
+13 additional authors

Document Type

Journal Article

Publication Date

5-1-2015

Journal

Journal of Neuro-Oncology

Volume

123

Issue

1

Inclusive Pages

85-91

DOI

10.1007/s11060-015-1764-7

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

DeWire, M., Fouladi, M., Turner, D., Wetmore, C., Hawkins, C., Hwang, E. I., & +13 additional authors (2015). An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).. Journal of Neuro-Oncology, 123 (1). http://dx.doi.org/10.1007/s11060-015-1764-7

Peer Reviewed

1

Open Access

1